Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanxinning Tablets for coronary heart disease with diabetic nephropathy
ChiCTR2100054422Phase 4Recruiting
- Sponsor
- Affiliated Hospital of Hangzhou Normal University
- Start
- Jun 2021
- Countries
- 1
01
Overview
Phase 4, open-label trial of Guanxinning in coronary arteriosclerosis and diabetic glomerulosclerosis (2 arms), sponsored by Affiliated Hospital of Hangzhou Normal University. Primary endpoints: 24-hour urine protein quantification, Estimated glomerular filtration rate and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
Guanxinning
03
Conditions
coronary arteriosclerosisdiabetic glomerulosclerosis
Beyond the preview
Go deeper on ChiCTR2100054422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054422.